What is DBV Technologies's market cap?

DBV Technologies (DBVT) has a market capitalization of $822.6M and trades on NASDAQ.

What is DBV Technologies's revenue and profitability?

DBV Technologies generated $5.0M in trailing twelve-month revenue with a net loss of $176.0M, representing a net margin of -3506.5%, with free cash flow of -$170.6M. These figures are based on the Q2 2026 filing.

Who are DBV Technologies's competitors?

DBV Technologies's key competitors include Vyome Holdings, Inc. Common Stock, Celldex Therapeutics, Inc, Kymera Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

What subsidiaries does DBV Technologies have?

DBV Technologies's subsidiaries include DBV Technologies Inc..

Where is DBV Technologies headquartered?

DBV Technologies is headquartered in France and employs approximately 105 people. It has been publicly traded since 2014.

DBV Technologies

DBVT

DBV Technologies is a late-stage specialty biopharmaceutical company developing a proprietary immunotherapy platform called Viaskin.

Market cap

$822.64M+220%

Revenue$5.0M+29.3%

Net income-$176.0M-43.7%

Free cash flow-$170.6M-92.6%

EPS (diluted)-$0.70+36.9%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q2 2026 report

July 16, 2026

Revenue$800.2KMiss by $89.4K EPS-$0.14Miss by $0.02

Read the full report

Next report

Oct 27, 2026 (in 3 months)

Revenue estimate$755.4K

EPS estimate-$0.16

Financials

Q2 2026

Income statement

See full

Revenue$700.0K-53.3%

Operating income-$50.6M-23.1%

Net income-$50.4M-20.3%

EPS (diluted)-$0.12+61.3%

Balance sheet

See full

Cash & equivalents$174.9M+69.5%

Total debt$7.7M+0.1%

Total equity$160.4M+86.1%

Total assets$223.2M+55.6%

Cash flow

See full

Operating cash flow-$52.6M-55.2%

CapEx$400.0K—

Free cash flow-$53.0M-56.3%

Valuation & ratios

Valuation

See full

Market cap$822.64M+220%

Enterprise value$655.44M+284%

P/S163.9×+95.4×

Profitability

See full

Operating margin-3,543.1%+523pp

Net margin-3,506.5%+442pp

FCF margin-3,399.3%+3,268pp

Returns & leverage

See full

Return on equity-142.7%-5.0pp

Debt / equity0×0.0×

Current ratio3.7×+1.3×

Competitors

By market cap

Kymera Therapeutics$9.1B+192%

Alumis Inc.$3.5B+728%

Celldex Therapeutics$2.8B+91.5%

Avalo Therapeutics$1.0B+1,348%

DBV Technologies$822.6M+209%

Q32 Bio$451.9M+1,561%

MDC

Medicus Pharma$18.0M-55.0%

HIN

Vyome Holdings, Inc.$14.0M—

By revenue growth

DBV Technologies+29.3%

Kymera Therapeutics-12.6%

Celldex Therapeutics-88.5%

By net margin

Kymera Therapeutics-611.96%-203pp

Alumis Inc.-2,825.7%—

DBV Technologies-3,506.54%-353pp

Avalo Therapeutics-7,965.76%—

Celldex Therapeutics-32,753.58%-30,388pp

Profile

DBV Technologies is a late-stage specialty biopharmaceutical company developing a proprietary immunotherapy platform called Viaskin. The company's core value proposition is its Epicutaneous Immunotherapy (EPIT) technology, which delivers allergens through a non-invasive skin patch to activate the immune system without introducing antigens into the bloodstream, thereby reducing the risk of systemic allergic reactions.

Competitive position

DBV is a pioneer in epicutaneous immunotherapy with a late-stage clinical pipeline specifically targeting the high-unmet-need pediatric food allergy market.

GeographiesUnited States, European Union

Customer segmentsPediatric healthcare, Specialty medicine

Business modelResearch and Development, Biopharmaceutical Product Development

SuppliersClinical trial investigators, Specialized medical device manufacturers, Regulatory agencies (FDA, EMA)

CustomersSpecialty allergists, Pediatricians, Health insurance payers, Specialty pharmacies

CountryFrance

Listed2014

Employees105.0

CEODaniel Tassé

SectorHealthcare

IndustryBiotechnology

Websitedbvtechnologies.com

FilingsSEC EDGAR

Ask your AI about DBV Technologies.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is DBV Technologies's market cap?: DBV Technologies (DBVT) has a market capitalization of $822.6M and trades on NASDAQ.
What is DBV Technologies's revenue and profitability?: DBV Technologies generated $5.0M in trailing twelve-month revenue with a net loss of $176.0M, representing a net margin of -3506.5%, with free cash flow of -$170.6M. These figures are based on the Q2 2026 filing.
Who are DBV Technologies's competitors?: DBV Technologies's key competitors include Vyome Holdings, Inc. Common Stock, Celldex Therapeutics, Inc, Kymera Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
What subsidiaries does DBV Technologies have?: DBV Technologies's subsidiaries include DBV Technologies Inc..
Where is DBV Technologies headquartered?: DBV Technologies is headquartered in France and employs approximately 105 people. It has been publicly traded since 2014.